Applied BioCode Corporation (TPE:6598)

Taiwan · Delayed Price · Currency is TWD

27.60

+0.85 (3.18%)

Oct 8, 2026, 1:30 PM CST

Market Cap	2.84B +22.4%
Revenue (ttm)	666.54M +68.4%
Net Income	-48.89M
EPS	-0.48
Shares Out	102.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	503,347
Open	27.60
Previous Close	26.75
Day's Range	27.15 - 28.10
52-Week Range	20.50 - 31.90
Beta	0.62
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2016

Country Cayman Islands

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6598

Full Company Profile

Financial Performance

In 2025, Applied BioCode's revenue was 475.20 million, an increase of 38.52% compared to the previous year's 343.07 million. Losses were -201.20 million, -22.85% less than in 2024.

Financial Statements